Time to PSA progression was @ months ( @ % confidence interval ( CI ) : @ , not reached ( NR ) ) for Arm A and @ months ( @ % CI : @ , NR ) for Arm B. Treatment discontinuation due to adverse events was more common in Arm A compared to Arm B ( @ vs. @ % ; p = @ ) .